Stockreport

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Aprea Therapeutics, Inc.  (APRE) 
PDF ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) d [Read more]